BofA Upgrades Acadia Pharmaceuticals to Buy After 25% Pullback BofA upgrades Acadia Pharmaceuticals (ACAD) to Buy from Neutral with a $29 price target. Credit: Acadia Pharmaceuticals Subscribe now Already have an account? Sign in.
